Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective conscientiously but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my last several shares. My 1st CytoDyn article, “CytoDyn: What To Do When It’s Too Good In order to Be True?”, set away the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire employment interview that I came away with a bad impression of the business.

Irony of irony, the bad viewpoint of mine of the business has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the technology and associated intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) and the first new drug application endorsement ($5 million), and also royalty payments of five % of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it has this single therapy and a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

Its opening banner on the site of its (below) shows an active business with diverse interests albeit focused on leronlimab, several illness types, multiple publications in addition to multiple delivering presentations.

Could it all be smoke cigarettes and mirrors? That is a question I have been asking myself with the really start of the interest of mine in this particular organization. Judging by the multiples of thousands of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a traditional battleground, or even some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *